Physical Activity as Intervention Against Age-related Loss of Muscle Mass and Function
Condition(s) studied
Investigational drug(s) / intervention(s)
Heavy resistance training: Supervised heavy resistance training three times weekly for 52 weeks.
Moderate intensity training: Moderate intensity training supervised once weekly and home based unsupervised two times weekly for 52 weeks.
Control: No training
Study summary
A minimum of 450 healthy individuals (62-70 years old) will be recruited.
Each individual will be randomized into one of three groups stratified according to gender (M/F), BMI (≤28/\>28), and 30 sec chair stand (≤11/\>11). The three groups are Heavy resistance training (n=150), moderate intensity training (n=150), and control (n=150, no training).
Assessments will be performed at baseline, after 12 months of intervention. Furthermore, follow up will be performed after 2,4,7, and 10 years.
The primary outcome is change in leg extensor power after the intervention and during follow up.
The primary hypothesis is that by applying the intention-to-treat analysis, the moderate intensity training group will increase leg extensor power just as much as the heavy resistance training group. The two training groups will increase muscle power more than the control group.
Eligibility
Primary outcome measure(s)
- Change in leg extensor power — Baseline, 1, 2, 4, 7, and 10 years follow up
Unilateral leg extension power measured in the Leg Extensor Power Rig device (Nottingham). The primary time interval for assessment of the primary outcome measure is from baseline to 12 months intervention. The statistical evaluation of the primary outcome measure is done by applying a two way ANOVA test comparing the three groups before/after the intervention and during follow up (1,2,4,7, and 10 years).
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Bispebjerg Hospital | Copenhagen NV | Denmark |
More Bispebjerg Hospital trials in Denmark
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT02123641 on ClinicalTrials.gov ↗ ← All trials in Denmark